SGLT2 Inhibitors' Growing Role Across Cardio-Kidney-Metabolic Care

Welcome back to another AJMC Insights series. In "SGLT2 Inhibitors' Growing Role Across Cardio-Kidney-Metabolic Care," Dr. Vaduganathan opens the series by tracing the rapid expansion of SGLT2 inhibitors across cardiovascular, kidney, and metabolic disease care.

Dr. Vaduganathan opens the series by describing how SGLT2 inhibitors have reshaped care across the entire cardio-kidney-metabolic landscape, moving from a single-specialty diabetes therapy into a foundational class used by cardiologists, nephrologists, and endocrinologists alike. He explains that guidelines now strongly recommend SGLT2 inhibitors for type 2 diabetes, chronic kidney disease, and heart failure, giving clinicians in each of those specialties a shared, evidence-based reason to reach for the class. That guideline consensus, he notes, has translated into growing clinical familiarity: as more specialties adopt the same recommendation, more clinicians see the drugs used, prescribe them themselves, and become comfortable with routine implementation. Dr. Vaduganathan points out that this momentum has accelerated markedly in recent years, reflecting both the accumulation of supportive trial data and the normalization of SGLT2 inhibitors as everyday therapy rather than a specialty niche.

A second driver, he explains, is the arrival of generic formulations. Generic entry has broadened access by lowering cost barriers that previously limited use, particularly for patients without generous prescription coverage. Dr. Vaduganathan argues that clinicians are increasingly aware of this shift toward generic availability, and that awareness itself is fueling renewed interest in implementing SGLT2 inhibitors, including in at-risk populations who have historically had less traditional access to newer, branded cardio-kidney-metabolic therapies. He frames this combination of strong guideline backing, rising familiarity, and improving affordability as evidence of a rapidly evolving therapeutic landscape. Dr. Vaduganathan closes his opening remarks by calling it an exciting one to watch, setting up the deeper discussion of guidelines, trial evidence, and implementation gaps that follows in later episodes.

The next episode in this series, "Guideline Recommendations and Implementation Gaps for SGLT2 Inhibitors," examines how specialty guidelines have positioned SGLT2 inhibitors and where real-world practice still lags behind.